Jakafi 20 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FCZA0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,677
Award facts
- Contract value 100% obligated
- $24,676.82 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $24,676.82 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 20 mg tablets (60-unit package). The contract employs firm fixed-price pricing with an ultimate completion date of December 8, 2025, and was executed without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion strategic acquisition vehicle designed to establish regional prime vendor contractors supplying comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract under PPV-G GEN V (designated SPE2DR) valued at $499,999,999 with an ultimate completion date of December 31, 2036, structured as a 30-month base period plus three 30-month option periods. The company's extensive product portfolio and demonstrated federal contracting activity—including specialized pharmaceuticals spanning oncology treatments, biologics, vaccines, and emergency medications—positions it as a critical supplier within the Defense Logistics Agency's military medical supply chain. The contractor maintains no identified subcontractor relationships and serves as one of multiple regional prime vendor contractors under the broader PPV-G GEN V framework.
Quick answers
Who was awarded contract SPE2DR26FCZA0?
SPE2DR26FCZA0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FCZA0 worth?
The government has obligated $24,677 on SPE2DR26FCZA0.
Is contract SPE2DR26FCZA0 an order under another contract?
Yes. SPE2DR26FCZA0 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZA0 competed?
The extent of competition for SPE2DR26FCZA0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award